Small-cell lung cancer in never-smokers
EntityUAM. Departamento de Medicina
PublisherBmj Publishing Group
10.1016/j.esmoop.2021.100059Esmo Open 6.2 (2021): 100059
Funded byThis work was supported by the Instituto de Salud Carlos III (ISCIII)/PI15/01211/Cofinanciado FEDER, Spanish Society of Neumology and Thoracic Surgery (Project number 848. 2019 call)
ProjectGobierno de España. PI15/01211
Subjectsnever-smokers; residential radon; small-cell lung cancer; survival; Medicina
Rights© 2021 The Author(s)
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Background: Lung cancer is a public health problem worldwide. Small-cell lung cancer (SCLC) is the most aggressive histologic type, with a 5-year survival <10%. SCLC is closely associated with tobacco consumption and infrequent in never-smokers. We aim to describe SCLC characteristics in never-smokers recruited in a radon-prone area. Patients and methods: We designed a multicentric case series where SCLC cases were recruited consecutively following histologic confirmation. Detailed information was obtained for indoor radon exposure, occupation and environmental tobacco smoke. We also collected different clinical characteristics such as extended or limited disease at diagnosis. Results: We recruited 32 never-smoking SCLC cases. Median age was 75 years and 87.5% were women; 47% had extended disease. Median radon concentration was 182 Bq/m3. There were no statistically significant differences in residential radon concentration neither regarding age at diagnosis nor regarding sex. The most frequent symptoms were constitutional syndrome (23.1%) and coughing (23.1%). As much as 63% of cases had an Eastern Cooperative Oncology Group Study (ECOG) status of 0-2. The 1- and 2-year survival rates were 34.4% and 21.9%, respectively. The 2-year survival rate with a localized tumor was 26.7%, compared with 18.8% for extended disease. Conclusions: These results show, for the first time, that indoor radon might not be associated with SCLC characteristics at diagnosis in never-smokers, and also confirms the low survival of this aggressive type of lung cancer also for never-smokers
Google Scholar:Torres-Durán, M. - Curiel-García, M. T. - Ruano-Ravina, A. - Provencio Pulla, Mariano - Parente-Lamelas, I. - Hernández-Hernández, J. - Fernández-Villar, A. - Barros-Dios, J. M. - Pérez-Ríos, M.
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group Provencio Pulla, Mariano; Terrasa, Josefa; Garrido, Pilar; Campelo, Rosario García; Aparisi, Francisco; Diz, Pilar; Aguiar, David; García-Giron, Carlos; Hidalgo, Julia; Aguado, Carlos; González, Jorge García; Esteban, Emilio; Gómez-Aldavarí, Lorenzo; Moran, Teresa; Juan, Oscar; Chara, Luís Enrique; Marti, Juan L.; Castro, Rafael López; Ortega, Ana Laura; Moreno, Elia Martínez; Coves, Juan; Sánchez Peña, Ana M.; Bosch-Barrera, Joaquim; Gastaldo, Amparo Sánchez; Núñez, Natalia Fernández; del Barco, Edel; Cobo, Manuel; Isla, Dolores; Majem, Margarita; Navarro, Fátima; Calvo de Juan, Virginia